Maven Pet, the trailblazing pet health company that specializes in using artificial intelligence (AI) to help veterinarians provide enhanced pet care to their patients, is collaborating with biotechnology leaders Cell Therapy Tools (CTT) in their quest to bring allogeneic cell-based therapies to market. CTT is embarking on a significant clinical investigation targeting patients suffering from canine Osteoarthritis (OA), a debilitating condition that affects the joints of many dogs.
CTT has developed a product named Chondroshield, which “has not only the ability to alleviate pain and inflammation but also an ability to actively stimulate joint restoration” according to Dr. Fari Izadyar, the company’s founder and CEO. The study seeks to further prove Chondroshield’s efficacy and therapeutic value in a clinical setting and will be conducted under the guidance of the United States Food and Drug Administration (FDA).
Maven Pet’s AI-powered platform will play a key role in the study by enhancing the diagnosis and continuous monitoring of OA in dogs, offering a fresh perspective on the disease and the behaviors exhibited by these pets throughout the various phases of this degenerative condition.
Maven’s role in the study
By harnessing Maven Pet’s expertise in pet health monitoring and leveraging its cutting-edge AI technology, the study will include real-time data concerning patterns of activity, sleep, and resting respiratory rates throughout its duration. This comprehensive data collection will facilitate a thorough comparison of pet activity and health patterns both before and after the administration of Chondroshield. Through this analysis, the study aims to extract invaluable insights into the progression and effectiveness of the treatment.
“Participating in this study is another important step for our company. From the beginning, we’ve focused on developing innovative solutions that use technology, and AI in particular, to improve the quality of life of pets.“ stated Guilherme Coelho, CEO of Maven Pet. “So we couldn’t be prouder of our involvement in this process. And just as Chondroshield has the potential to alleviate the suffering of the many dogs struggling with a debilitating disease such as canine Osteoarthritis, we look forward to helping enhance similar studies that break new ground in the fight against other conditions.”
The study will be overseen by Dr. Robert “Jeff” Mayo, a distinguished small animal orthopedic surgeon and Chief Veterinary Medical Officer at CTT. It is slated to commence in the state of Washington, with CTT now enrolling canine patients suffering from Osteoarthritis. Pet owners interested in learning more about the trial are encouraged to contact CTT at https://celltherapytools.com/contact-us, or call 949-630-2050.
For media inquiries or additional information about Maven Pet and its AI-powered platform, please contact [email protected] .
About Maven Pet
Maven Pet focuses on improving the quality of life of our pets with technology, using artificial intelligence (AI) to enable proactive pet care. By accurately collecting and monitoring pet data 24/7 and flagging any irregularities, Maven Pet empowers pet parents and veterinarians to stay ahead of potential health issues, ensuring the well-being and longevity of our beloved companions.
